Jeffrey S. Parkin

Array ( [id] => 4186512 [patent_doc_number] => 06042831 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-03-28 [patent_title] => 'Human immunodeficiency virus type 1 (HIV-1) GP160 epitopes that are immunologically homologous to epitopes located in the class I major histocompatibility complex (MHC) heavy chain .alpha.-1 domain' [patent_app_type] => 1 [patent_app_number] => 8/335733 [patent_app_country] => US [patent_app_date] => 1994-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 9135 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/042/06042831.pdf [firstpage_image] =>[orig_patent_app_number] => 335733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3729313 [patent_doc_number] => 05693508 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-12-02 [patent_title] => 'Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats' [patent_app_type] => 1 [patent_app_number] => 8/336132 [patent_app_country] => US [patent_app_date] => 1994-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 29776 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/693/05693508.pdf [firstpage_image] =>[orig_patent_app_number] => 336132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4042325 [patent_doc_number] => 05968514 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-10-19 [patent_title] => 'Methods for stimulating immune responses in a host through the administration of superantigen peptides derived from human immunodeficiency virus type 1 Nef' [patent_app_type] => 1 [patent_app_number] => 8/331454 [patent_app_country] => US [patent_app_date] => 1994-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13281 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/968/05968514.pdf [firstpage_image] =>[orig_patent_app_number] => 331454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3662256 [patent_doc_number] => 05667964 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-09-16 [patent_title] => 'Rapid, direct, and qualitative method for the determination of the number of HIV-1-infected patient cells employing reactive oxygen intermediate generators' [patent_app_type] => 1 [patent_app_number] => 8/331218 [patent_app_country] => US [patent_app_date] => 1994-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9492 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/667/05667964.pdf [firstpage_image] =>[orig_patent_app_number] => 331218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4291386 [patent_doc_number] => 06197496 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-03-06 [patent_title] => 'Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80' [patent_app_type] => 1 [patent_app_number] => 8/321566 [patent_app_country] => US [patent_app_date] => 1994-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 13132 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/197/06197496.pdf [firstpage_image] =>[orig_patent_app_number] => 321566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3784996 [patent_doc_number] => 05736378 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-04-07 [patent_title] => 'Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR' [patent_app_type] => 1 [patent_app_number] => 8/325547 [patent_app_country] => US [patent_app_date] => 1994-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 27 [patent_no_of_words] => 18474 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/736/05736378.pdf [firstpage_image] =>[orig_patent_app_number] => 325547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6648923 [patent_doc_number] => 20030104576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-06-05 [patent_title] => 'DNA CONSTRUCT, COMPOSITION, FORMULATIONS & METHODS FOR MAKING THE CONSTRUCT & FOR MODULATING EXPRESSION' [patent_app_type] => new [patent_app_number] => 08/319974 [patent_app_country] => US [patent_app_date] => 1994-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5995 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0104/20030104576.pdf [firstpage_image] =>[orig_patent_app_number] => 08319974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3601255 [patent_doc_number] => 05578496 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-11-26 [patent_title] => 'Detection of autoantibodies associated with the disease myasthenia gravis' [patent_app_type] => 1 [patent_app_number] => 8/318200 [patent_app_country] => US [patent_app_date] => 1994-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 15 [patent_no_of_words] => 19247 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/578/05578496.pdf [firstpage_image] =>[orig_patent_app_number] => 318200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3632045 [patent_doc_number] => 05610035 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-03-11 [patent_title] => 'Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies' [patent_app_type] => 1 [patent_app_number] => 8/313572 [patent_app_country] => US [patent_app_date] => 1994-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3949 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/610/05610035.pdf [firstpage_image] =>[orig_patent_app_number] => 313572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3868027 [patent_doc_number] => 05763190 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-06-09 [patent_title] => 'Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein' [patent_app_type] => 1 [patent_app_number] => 8/309644 [patent_app_country] => US [patent_app_date] => 1994-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15743 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/763/05763190.pdf [firstpage_image] =>[orig_patent_app_number] => 309644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3989175 [patent_doc_number] => 05919465 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-07-06 [patent_title] => 'Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S)' [patent_app_type] => 1 [patent_app_number] => 8/309717 [patent_app_country] => US [patent_app_date] => 1994-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 52 [patent_no_of_words] => 13509 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/919/05919465.pdf [firstpage_image] =>[orig_patent_app_number] => 309717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3842949 [patent_doc_number] => 05766598 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-06-16 [patent_title] => 'Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products' [patent_app_type] => 1 [patent_app_number] => 8/303275 [patent_app_country] => US [patent_app_date] => 1994-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 47949 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/766/05766598.pdf [firstpage_image] =>[orig_patent_app_number] => 303275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3980143 [patent_doc_number] => 05861161 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-01-19 [patent_title] => 'Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions' [patent_app_type] => 1 [patent_app_number] => 8/301915 [patent_app_country] => US [patent_app_date] => 1994-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 16 [patent_no_of_words] => 6180 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/861/05861161.pdf [firstpage_image] =>[orig_patent_app_number] => 301915 [rel_patent_id] =>[rel_patent_doc_number] =>)